Institute of Gynecology and Obstetrics, Sapienza University, Rome, Italy.
Invest New Drugs. 2010 Dec;28(6):887-94. doi: 10.1007/s10637-009-9351-4. Epub 2009 Nov 24.
Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life. Here we report the case of a patient who benefited from complete resolution of ascites after low dose intraperitoneal administration of bevacizumab. Immunological analyses showed an initial increase in proportion and function of CD8(+) effector T cells and a reduction of circulating T(reg) cells. A review of the current literature regarding bevacizumab in ovarian cancer is reported. Bevacizumab has shown a high efficacy in the treatment of ovarian cancer. Intraperitoneal administration induces an immune activation and appears promising in the treatment of malignant ascites.
恶性腹水对常规药物耐药，常影响卵巢癌患者的生命末期。本文报道了 1 例低剂量腹腔内给予贝伐珠单抗治疗后完全缓解腹水的患者。免疫分析显示 CD8(+)效应 T 细胞的比例和功能最初增加，而循环 T(reg)细胞减少。本文还对卵巢癌贝伐珠单抗的相关文献进行了综述。贝伐珠单抗在治疗卵巢癌方面显示出很高的疗效。腹腔内给药可诱导免疫激活，在治疗恶性腹水方面有较好的应用前景。
